Nippon Investment Bespoke Research UK Ltd

Nippon Investment Bespoke Research UK

Equity Bottom-Up

<ul><li>Medical Data Vision’s [MDV] produced FY25 (Dec year-end) Q3 gross profit [GP] of ¥3,248mil (+6.3% YoY) and operating profit [OP]of ¥95mil (vs FY24 Q3’s operating loss of -¥140mil) on sales of ¥4,650mil (+12.7% YoY).</li><li>FY25 is the last year of the ongoing 3-year medium-term management plan [MTP].</li><li>MDV revised down the FY25 guidance on 14 October from OP of ¥2,600mil (vs a recovery from ¥3mil in FY24) on sales of ¥9,000mil (+52.4% YoY) to OP of ¥490mil on sales of ¥6,860mil (+16.1% YoY).</li></ul>

Medical Data Vision’s [MDV] produced FY25 (Dec year-end) Q3 gross profit [GP] of ¥3,248mil (+6.3% YoY) and operating profit [OP]of ¥95mil (vs FY24 Q3’s operating loss of -¥140mil) on sales of ¥4,650mil (+12.7% YoY).FY25 is the last year of the ongoing 3-year medium-term management plan [MTP].MDV revised down the FY25 guidance on 14 October from OP of ¥2,600mil (vs a recovery from ¥3mil in FY24) on sales of ¥9,000mil (+52.4% YoY) to OP of ¥490mil on sales of ¥6,860mil (+16.1% YoY).

Medical Data Vision Co., Ltd (3902 JP): RESEARCH UPDATE

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>For February 2026, 12 new transactions (firm and non-binding) were discussed on Smartkarma (by the Quiddity team) with an overall announced deal size of ~US$7bn.</li>
<li>The average premium for the new transactions announced (or first discussed) in February was ~42%.</li>
<li>The average premiums for transactions in 2025, 2024, 2023, 2022, 2021, 2020, and 2019 were 49%, 43%, 39%, 41%, 33%, 31%, and 31%.</li>
</ul>


For February 2026, 12 new transactions (firm and non-binding) were discussed on Smartkarma (by the Quiddity team) with an overall announced deal size of ~US$7bn.
The average premium for the new transactions announced (or first discussed) in February was ~42%.
The average premiums for transactions in 2025, 2024, 2023, 2022, 2021, 2020, and 2019 were 49%, 43%, 39%, 41%, 33%, 31%, and 31%.


Asia-Pac M&A, Feb 2026 Wrap: MCJ, Magnetic Res, Inforich, Pepper Money, Takara Bio, Qoria

<ul>
<li>I tally 34 - mostly firm, mostly Asia-Pac - arb transactions currently being discussed and analysed on Smartkarma. Those arbs metrics and upcoming events are detailed below.</li>
<li>Two new deals were discussed on Smartkarma this week: Aura's scrip Offer for <a href="https://www.smartkarma.com/entities/qoria-ltd" target="_blank" data-smartkarma-citation="entities:30531:1" rel="noopener">Qoria (QOR AU)</a> and backdoor listing; and <a href="https://www.smartkarma.com/entities/guocoland-ltd" target="_blank" data-smartkarma-citation="entities:17467:1" rel="noopener">GuocoLand (GUOL SP)</a>'s selective capital reduction for <a href="https://www.smartkarma.com/entities/guocoland-malaysia-bhd" target="_blank" data-smartkarma-citation="entities:16496:1" rel="noopener">Guocoland Malaysia (GUOL MK)</a>.</li>
<li>Key updates/news also took place on: <a href="https://www.smartkarma.com/entities/apiam-animal-health-ltd" target="_blank" data-smartkarma-citation="entities:26109:1" rel="noopener">Apiam Animal Health (AHX AU)</a>, <a href="https://www.smartkarma.com/entities/humm-group" target="_blank" data-smartkarma-citation="entities:35366:1" rel="noopener">Humm (HUM AU)</a>, <a href="https://www.smartkarma.com/entities/qube-holdings-ltd" target="_blank" data-smartkarma-citation="entities:958:1" rel="noopener">Qube (QUB AU)</a>,<a href="https://www.smartkarma.com/entities/medical-data-vision-co-ltd" target="_blank" data-smartkarma-citation="entities:8367:1" rel="noopener">Medical Data Vision (3902 JP)</a>, <a href="https://www.smartkarma.com/entities/raksul-inc" target="_blank" data-smartkarma-citation="entities:27043:1" rel="noopener">Raksul (4384 JP)</a>, and <a href="https://www.smartkarma.com/entities/ijm-corp-bhd" target="_blank" data-smartkarma-citation="entities:16784:1" rel="noopener">Ijm Corp (IJM MK)</a>.</li>
</ul>


I tally 34 - mostly firm, mostly Asia-Pac - arb transactions currently being discussed and analysed on Smartkarma. Those arbs metrics and upcoming events are detailed below.
Two new deals were discussed on Smartkarma this week: Aura's scrip Offer for Qoria (QOR AU) and backdoor listing; and GuocoLand (GUOL SP)'s selective capital reduction for Guocoland Malaysia (GUOL MK).
Key updates/news also took place on: Apiam Animal Health (AHX AU), Humm (HUM AU), Qube (QUB AU),Medical Data Vision (3902 JP), Raksul (4384 JP), and Ijm Corp (IJM MK).


Asia-Pac M&A Weekly Wrap: Qoria, Guocoland Malaysia, Humm, Qube, Medical Data Vision, Raksul, IJM

<ul>
<li>Investors see value in <a href="https://www.smartkarma.com/entities/toyota-industries-corp" target="_blank" data-smartkarma-citation="entities:4500:1" rel="noopener">Toyota Industries (6201 JP)</a>. Many are concerned TICO and TM will deliberately engage in bad corporate governance to punish minorities if the Offer doesn't go through.</li>
<li>It's doubtful an international tribunal has the clout to overturn <a href="https://www.smartkarma.com/entities/ck-hutchison-holdings-ltd" target="_blank" data-smartkarma-citation="entities:132:1" rel="noopener">CKH (1 HK)</a>'s Supreme Court decision. The safe takeaway here is that this entire construct won't be concluded anytime soon.</li>
<li>
<a href="https://www.smartkarma.com/entities/melco-international-development-ltd" target="_blank" data-smartkarma-citation="entities:809:1" rel="noopener">Melco International Development (200 HK)</a>'s divergence with <a href="https://www.smartkarma.com/entities/melco-crown-entertainme-adr" target="_blank" data-smartkarma-citation="entities:810:1" rel="noopener">Melco Resorts &amp; Entertainment (MLCO US)</a> is a curious thing. Is a statutory merger in the wings?</li>
</ul>


Investors see value in Toyota Industries (6201 JP). Many are concerned TICO and TM will deliberately engage in bad corporate governance to punish minorities if the Offer doesn't go through.
It's doubtful an international tribunal has the clout to overturn CKH (1 HK)'s Supreme Court decision. The safe takeaway here is that this entire construct won't be concluded anytime soon.

Melco International Development (200 HK)'s divergence with Melco Resorts &amp; Entertainment (MLCO US) is a curious thing. Is a statutory merger in the wings?


Last Week In Event SPACE: CKH, Toyota Industries, Melco, Rio/Glencore, Guoco

Hisamitsu Pharmaceutical Co / Event-Driven

<ul>
<li>For January 2026, 6 new transactions (firm and non-binding) were discussed on Smartkarma (by the Quiddity team) with an overall announced deal size of ~US$8bn.</li>
<li>The average premium for the new transactions announced (or first discussed) in January was ~42%.</li>
<li>The average premiums for transactions in 2025, 2024, 2023, 2022, 2021, 2020, and 2019 were 49%, 43%, 39%, 41%, 33%, 31%, and 31%.</li>
</ul>


For January 2026, 6 new transactions (firm and non-binding) were discussed on Smartkarma (by the Quiddity team) with an overall announced deal size of ~US$8bn.
The average premium for the new transactions announced (or first discussed) in January was ~42%.
The average premiums for transactions in 2025, 2024, 2023, 2022, 2021, 2020, and 2019 were 49%, 43%, 39%, 41%, 33%, 31%, and 31%.


Asia-Pac M&A, Jan 2026 Wrap: Hisamitsu Pharma, IJM Corp, Sankei Real Estate, BioDlink, Skyworth

Japan

Medical Data Vision Co.,Ltd. was founded in 2003. The company's line of business includes developing integrated medical information systems, analysis of medical information, and business consulting for medical institutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medical Data Vision (3902 JP)

Medical Data Vision Co., Ltd (3902 JP): RESEARCH UPDATE

Medical Data Vision’s [MDV] produced FY25 (Dec year-end) Q3 gross profit [GP] of ¥3,248mil (+6.3% YoY) and operating profit [OP]of ¥95mil (vs FY24...

Nippon Investment Bespoke Research UK

Asia-Pac M&A, Feb 2026 Wrap: MCJ, Magnetic Res, Inforich, Pepper Money, Takara Bio, Qoria

For the month of Feb 2026, 12 new deals were discussed on Smartkarma with an overall deal size of just ~US$7bn. The average premium for the new...

David Blennerhassett

Asia-Pac M&A Weekly Wrap: Qoria, Guocoland Malaysia, Humm, Qube, Medical Data Vision, Raksul, IJM

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

David Blennerhassett

Last Week In Event SPACE: CKH, Toyota Industries, Melco, Rio/Glencore, Guoco

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

David Blennerhassett

Asia-Pac M&A, Jan 2026 Wrap: Hisamitsu Pharma, IJM Corp, Sankei Real Estate, BioDlink, Skyworth

For the month of Jan 2026, 6 new deals were discussed on Smartkarma with an overall deal size of ~US$8bn. The average premium for these new deals...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)